FoVi: Wearable Focal Muscle Vibration for Precision Rehabilitation

Votes: 3
Views: 1702

FoVi is a wearable focal muscle vibration device that can be worn at different locations of muscles and muscle groups on a human. It is an innovative device with feedback control to provide precise vibration therapy to target muscles/muscle groups for neurorehabilitation. FoVi and be worn and used while user at rest or performing activities of daily living. It can be used at clinical settings, community and home environment. In addition, there is a Smartphone App to provide patients real time feedback on the usage of the vibration therapy. In addition, the App connect to a web portal which allows therapist or healthcare professionals to monitor and track the usage of the device, as well as allows them to remotely adjust the vibration dosage and duration based on the rehabilitation progress of patients. Preliminary clinical trials have demonstrated that usage of FoVi improved the balance and mobility for patients with multiple sclerosis and diabetes. It is also evident that usage of FoVi reduced the pain and increased the sensation for patients with diabetic peripheral neuropathy. There is no adverse event associated with applying the technology and patients’ feedback on the technology is enjoyable and comfort.



Voting is closed!


  • Name:
    Hongwu Wang
  • Type of entry:
    Team members:
    Hongwu Wang, Mustafa Ghazi, Josiah Rippetoe
  • Profession:
  • Number of times previously entering contest:
  • Hongwu is inspired by:
    Congestive heart failure (CHF) is a common disease affecting the aging population and is the leading cause of mortality worldwide despite significant progress in detecting, monitoring, and treating the illness over the last century. CHF is one of the costliest disease syndromes affecting over 64 million people worldwide, with treatment costing an estimated $30.7 billion in the United States alone in 2012. Moreover, from both current clinical standard care and home health monitor perspectives, the management of CHF, especially the early detection and treatment remains a significant health challenge, necessitating the development of parallel and complementary approaches for reliable non-invasive diagnostic and monitoring solutions. The situation became worse as the aging population kept increasing. More than 90% of CHF deaths occur in adults older than 65 years.
  • Software used for this entry:
  • Patent status: